Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

December 20, 2023

https://www.globenewswire.com/news-release/2023/12/20/2799681/0/en/Annexon-Announces-Pricing-of-125-0-Million-Underwritten-Public-Offering-of-Common-Stock.html

BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The shares of common stock are being sold at a price of $2.88 per share and the pre-funded warrants are being sold at a price of $2.879 per share.

Read more at globenewswire.com

Related news for (ANNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.